my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
01-26-2011: Swissmedic, the Swiss Agency for Therapeutic Products, and the Australian Therapeutic Goods Administration (TGA) have granted approval for Gilenya® (fingolimod) 0.5 mg as a first-line, oral disease-modifying therapy (DMT) for the treatment of relapsing-remitting multiple sclerosis (RRMS).
"Gilenya, with its innovative mechanism of action, can improve clinical outcomes in patients with relapsing remitting MS," said Professor Ludwig Kappos, Neurology and Department of Research, University Hospital, Basel, Switzerland. "The significant efficacy and manageable safety profile of Gilenya make it a valuable new option for patients with relapsing-remitting MS and the physicians who treat them."
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Swissmedic, the Swiss Agency for Therapeutic Products, and the Australian Therapeutic Goods Administration (TGA) have granted approval for Gilenya® (fingolimod) 0.5 mg as a first-line, oral disease-modifying therapy (DMT) for the treatment of relapsing-remitting multiple sclerosis (RRMS)."G ... more
Discontinuation of sale of ceftobiprole in Switzerland
Basilea Pharmaceutica Ltd. announces that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera(TM)) for the treatment of complicated skin and soft tissue infections (cSSTI) in Switzerland. Janssen-Cilag AG, the holder of the Marketing Authoriza ... more
Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new therapeutic option for newly diagnosed patients ... more
Ablynx noted that a paper on a novel tetrameric Nanobody® agonist (TAS266) targeting Death Receptor 5 (DR5), a key receptor target on cancer cells across a number of tumour types, was presented at the American Association for Cancer Research Annual Meeting in Chicago by Novartis. The abilit ... more
Ablynx receives milestone payment as collaborator receives IND approval for a nanobody in oncology
Ablynx announced that it has received a €400,000 milestone payment from its collaboration with Novartis. The payment was triggered by the approval of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration for the Phase I clinical trial for a Nanobody® licen ... more
The Journal of the American Medical Association (JAMA) published a study that shows Bexsero induced a robust immune response against meningococcal B disease in the vast majority of infants vaccinated. These results also show that Bexsero can fit into various vaccination schedules in the fir ... more
We focus on the well-being of companion animals and the health and productivity of farm animals. Our extensive product range provides solutions for the prevention and treatment of various widespread animal diseases and parasite infestations. The majority of these products are available by p ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
